Nluc Reporter Cell Line - LN229

LN229 is a human glioblastoma cell line derived from a 60-year-old Caucasian female patient with glioblastoma multiforme (GBM), specifically a glioblastoma located in the right frontoparietal occipital cortex. LN229 cells exhibit an epithelial-like morphology and adherent growth characteristics. LN229 cells display typical features of malignant glioma cells, including aggressive growth patterns and resistance to conventional therapies. These cells are commonly used in studies of tumorigenesis, cell signaling pathways, and responses to therapeutic agents. Their genomic characteristics, including mutations in genes such as PTEN and TP53, make them a valuable model for studying the molecular mechanisms of glioblastoma progression and treatment resistance. Due to their high tumorigenic potential, they readily form tumors when injected into nude mice. Researchers utilize LN229 cells in both in vitro and in vivo models to explore novel therapeutic strategies, including targeted therapies and immunotherapies, providing insights into potential clinical applications.

The Nluc reporter cell line - LN229 is an engineered variant of the LN229 cell line, into which the NanoLuc luciferase (Nluc) reporter gene has been introduced. This modification enables highly sensitive luminescence-based detection, facilitating real-time monitoring of cellular processes and responses. The primary applications of this reporter gene cell line are in high-throughput drug screening and mechanistic studies. Researchers assess the efficacy and cytotoxicity of anticancer compounds by measuring changes in luminescence intensity, which correlates with cell viability and proliferation. Furthermore, the Nluc reporter gene can be used to study specific signaling pathways; for example, by coupling the reporter gene to promoters responsive to hypoxia or inflammation, scientists can study the dynamics of the tumor microenvironment. This cell line is also valuable in in vivo models, where bioluminescence imaging allows for real-time tracking of tumor growth, metastasis, and treatment response.